DIANA technology can be advantageously used not only for effective kinase inhibitor profiling, but any DIANA assay available in our profiling portfolio can be readily transformed into the powerful high-throughput screening (HTS) assay. In this setup, screened compounds compete with the DIANA probe for the target binding. It offers sensitive hit discovery (ultra-low false-positive and false-negative rate) while providing direct quantification of the compound’s inhibition potency (Kd). It also allows highly efficient screening of pooled libraries leading to a reduced screening cost and time.
This makes it suitable not only for large pharma high-throughput-screening facilities but also for smaller-scale projects at academic institutions (in-house libraries of ~10k compounds can be screened in just several 384-well plates). Finally, we can also offer a characterization of ADME properties of identified lead compounds that can emerge from the HTS campaigns.
Download the complete HTS Leaflet
Document name | Download |
|---|---|
Pick the library and send us your requirements
Fragment-based libraries, composed of low molecular weight and structurally diverse molecules, play a crucial role in high-throughput screening to identify promising drug leads for subsequent optimization. Through our HTS services, you gain access to these libraries along with focused compound collections for targeted screening. We provide a variety of assay options, including established inhibitor profiling assays and custom-designed assays developed on demand to suit your target and research goals. The service turn-around time and price depend on the project complexity.
Fragment-based libraries: Lead-like diversity set and Drug-like discovery set
Focused libraries: Kinase inhibitor library and FDA-approved drug library
Containing appx. 10,000 compounds (over 6,000 scaffolds)
Compounds with low MW (MW<400 Da) and logP (0-3)
No PAINS, only medchem friendly compounds
Drug Discovery Services
We transform any DIANA assay into a high-throughput screening (HTS) platform, enabling sensitive hit discovery with direct potency (Kd) readout. Our approach allows efficient pooled library screening, reducing cost and time and is suitable for both pharma and academic projects.
Our assays deliver robust and reproducible results across a wide range of targets, including those considered challenging. This reliability helps minimize project setbacks and ensures greater confidence in your screening outcomes.
We can establish and deliver high-throughput screening (HTS) services within 3 months. This accelerated setup significantly shortens early discovery timelines and allows you to quickly move from assay design to actionable results.
DIANA assays can be developed as stand-alone services tailored to your specific project needs, or seamlessly integrated into broader collaborative programs. This flexibility makes them suitable for both large pharma pipelines and smaller academic initiatives.
To support your project goals, we provide models with defined performance milestones and risk-sharing options. This ensures transparency, reduces upfront risk, and aligns our success directly with your discovery outcomes.
